BioCentury | Dec 16, 2016
Company News

SOM Biotech deal

...SOM said that in November it granted an undisclosed company worldwide rights to tolcapone (SOM0226). The...
...amyloidosis. SOM declined to disclose additional details. SOM Biotech S.L. , Barcelona, Spain Business: Endocrine/Metabolic Alicia Parker SOM0226 Tolcapone SOM...
BioCentury | Nov 2, 2016
Distillery Therapeutics

Neurology

...CNS. Next steps include further optimization of the compounds. Roche markets the COMT inhibitor Tasmar tolcapone...
BioCentury | May 19, 2016
Distillery Therapeutics

Therapeutics: Catechol-O-methyl-transferase (COMT)

...that inhibited the activity of human COMT with greater potency than the COMT inhibitors Tasmar tolcapone...
...nM, respectively). In a human liver cell line, the compound induced less mitochondrial toxicity than Tasmar...
...toxicity comparable to Comtan. Next steps include testing the inhibitor in PD models. Roche markets Tasmar...
BioCentury | Dec 7, 2015
Regulation

Action in amyloidosis

...TTR antisense inhibitor Ph II/III for FAP mNIS+7 and Norfolk QOL questionnaire SOM Biotech S.L. Tolcapone...
BioCentury | Nov 9, 2015
Clinical News

Tolcapone: Phase IIa data

...Congress on Hereditary ATTR amyloidosis meeting in Paris. SOM Biotech S.L. , Barcelona, Spain Product: Tolcapone...
BioCentury | Nov 4, 2015
Clinical News

Alnylam, SOM Biotech, Isis update TTR programs

...delivery platform. Data in an abstract from a Phase IIa study of SOM Biotech's SOM0226 tolcapone...
...stabilizer of tetrameric TTR and a TTR fibril disruptor. Roche (SIX:ROG; OTCQX:RHHBY) markets tolcapone as Tasmar...
BioCentury | Aug 11, 2008
Company News

Meda, Valeant Pharmaceuticals International deal

...the North American market. The deal includes Valeant’s Mestinon pyridostigmine to treat myasthenia gravis; Tasmar tolcapone...
BioCentury | Aug 5, 2008
Company News

Meda acquiring Valeant units in Europe

...is the North American market. The deal includes Mestinon pyridostigmine to treat myasthenia gravis; Tasmar tolcapone...
BioCentury | Jan 22, 2007
Company News

Jazz, Valeant Pharmaceuticals International deal

...Xyrem, which is approved in Canada, to launch mid-year. VRX markets Zelapar selegiline and Tasmar tolcapone...
BioCentury | Feb 27, 2006
Clinical News

Tasmar regulatory update

...FDA approved less restrictive labeling for Tasmar to treat Parkinson's disease (PD) in patients undergoing treatment...
...for less frequent laboratory monitoring for patients taking Tasmar, and allows patients to remain on Tasmar...
...European and U.S. rights to Tasmar from ROCZ in 2004 (see BioCentury, Sept. 20, 2004). Tasmar...
Items per page:
1 - 10 of 15